Profitability
Weight: 20%
B
70
- 5yr Avg ROIC 158.6%
- Operating Margin Trend -17845.75 pp/yr
INBX
Inhibrx Biosciences, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
A+
100
- 5yr Avg ROE 2700.3%
- 5yr Share-Count CAGR -20.1%
Growth Quality
Weight: 15%
F
11
- 5yr Revenue CAGR -34.6%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 1/5
Cash Generation
Weight: 15%
F
0
- 5yr FCF Margin -25183.0%
- 5yr FCF/NI Conversion -0.12x
Balance Sheet
Weight: 20%
F
4
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -11.07x
- Altman Z-Score 1.03
Stability
Weight: 15%
C+
60
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 3
- Negative-Revenue Years (5) 4/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 1 new buy.
- Holders
- 3 +1
- Avg Δ position
- 0.0%
- New buys
- 1
- Full exits
- 0
- Laffont new